Crescita Therapeutics Reports Fourth Quarter and Fiscal 2018 Results Record Annual Revenue of $16.6M and Adjusted EBITDA of $1.5M Strong Royalties and Sales Milestones

Stock Information for Crescita Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Crescita Therapeutics Inc.

United States Patent and Trademark Office Issues U.S. Patent Covering an Enhanced Formulation of Pliaglis®
Crescita Therapeutics to Host Investor Webcast on July 24, 2019
Crescita Therapeutics Inc. Receives 2nd Instalment of Up-Front Payment of Euro1.25 Million Following First Commercial Sale of Pliaglis by Cantabria in Italy
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid
Crescita Therapeutics Inc. Announces Intention to Make Normal Course Issuer Bid
Crescita to Present at the 9th Annual LD Micro Invitational in Los Angeles, California
Crescita Therapeutics Engages Bristol Capital to Provide Investor Relations and Communications Services
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.